Autres langues Emmaus Life Sciences, Inc.

Actions

EMMA

US29137T1016

Marché Fermé - OTC Markets Autres places de cotation 21:40:36 03/05/2024			Varia. 5j.	Varia. 1 janv.
0,1 ^USD	-1,53 %		0,00 %	-0,10 %

02/02	Emmaüs Life Sciences, Inc. reçoit l'autorisation de mise sur le marché du ministère de la Santé de Porto Rico pour Endari® (poudre orale de L-glutamine)	CI
2023	Emmaus Life Sciences, Inc. publie ses résultats pour le troisième trimestre et les neuf mois clos le 30 septembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Emmaus Life Sciences Reports Delayed Filing of Annual Report	15/04
Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico	02/02
Emmaus Life Sciences, Inc. Receives Marketing Authorization from the Puerto Rico Department of Health for Endari® (L-Glutamine Oral Powder)	02/02
Emmaus Life Sciences : Material Agreement - Form 8-K	20/12
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q3 Revenue $5M	14/11
Emmaus Life Sciences Reports Q3 2023 Financial Results	14/11
Emmaus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Emmaus Life Sciences, Inc. Announces Board Changes	04/10/23
Emmaus Life Sciences Reports Management Changes	23/08/23
Emmaus Life Sciences, Inc. Announces Yutaka Niihara No Longer Serve as Chief Executive Officer	23/08/23
Emmaus Life Sciences, Inc. Announces Management Changes	23/08/23
Emmaus Life Sciences Reports Q2 2023 Financial Results	14/08/23
Emmaus Life Sciences : Reports Q2 2023 Financial Results - Form 8-K	14/08/23
Emmaus Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman	13/07/23
Emmaus Life Sciences, Inc Receives Marketing Authorization for EndariÂ® in Oman	13/07/23
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA	31/05/23
Emmaus Life Sciences, Inc. Receives Medicine Registration Certificate from the Bahrain National Health Regulatory Authority	31/05/23
Emmaus Life Sciences, Inc. Receives Medicine Registration Certificate from the Bahrain National Health Regulatory Authority	31/05/23
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q1 Revenue $6.8M	15/05/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Emmaus Life Sciences, Inc.

Actions

EMMA

US29137T1016

Autres langues

Filtres